News

Article

Study: Prevalence of myopic macular degeneration in those 85 years and older

Author(s):

(Image Credit: AdobeStock/kohanova1991)

(Image Credit: AdobeStock/kohanova1991)

The takeaway message from a population-based study of very old, highly myopic individuals found a high risk of developing myopic maculopathy and marked visual impairment,1 according to first author Mukharram M. Bikbov, MD, from the Ufa Eye Research Institute, Ufa, Russia.

The investigators explained that with older age a risk factor for the development of myopic macular degeneration (MMD), the aging of a young myopic generation may result in even more visual impairment and blindness as the result of myopic macular degeneration.2

They conducted a study to assess the prevalence of and associations of MMD in very old individuals recruited in a population-based manner. They then compared the results with the findings from another population-based study previously conducted with a similar study design and in the same geographic region on younger individuals.

The Ural Very Old Study included 1,526 of 1,882 eligible individuals who were 85 years and older; 60.9% of these (930 individuals; mean age, 88.6 years) had fundus images available for assessment.

The authors explained that MMD was defined by the presence of macular patchy atrophies (stages 3 and 4 as defined by the Pathologic Myopia Study Group3).

MMD prevalence

MMD was found in 21 of 930, for a prevalence rate of 2.3% (95% confidence interval [CI], 1.3–3.3). Ten individuals had stage 3 MMD and 11 participants had stage 4 MMD.

In those 2 stages, the authors reported that “the prevalence of binocular moderate-to-severe vision impairment was 4 of 10 (40%; 95% CI, 31–77) and 7 of 11 (64%; 95% CI, 30–98), respectively, and the prevalence of binocular blindness was 2 of 10 (20%; 95% CI, 0–50) and 3 of 11 (27%; 95% CI, 0–59), respectively.”

An analysis of the axial lengths showed that in low myopia (axial length, 24.0 to <24.5 mm), moderate myopia (axial length, 24.5 to <26.5 mm), and high myopia (axial length, ≥26.5 mm), the respective MMD prevalence rates in the right eyes were 0 of 46 eyes (0%), 3 of 40 eyes (8%; 95% CI, 0–16), and 7 of 9 (78%; 95% CI, 44–100) and the respective MMD prevalence rates in the left eyes were 1 in 48 eyes (2%; 95% CI, 0–6), 4 of 36 eyes (11%; 95% CI, 0–22), and 3 of 4 eyes (75%; 95% CI, 0–100).

Multivariable analysis showed that a higher MMD prevalence rate (odds ratio, 8.89; 95% CI, 3.43–23.0) and a higher MMD stage (beta, 0.45; B, 19; 95% CI, 0.16–0.22) (p < 0.001 for both comparisons) were correlated with longer axial length but not any other ocular or systemic parameter.

Bikbov and colleagues concluded, “The MMD prevalence (stages 3 and 4) in very old individuals increased 8.89-fold for each millimeter increase in the axial length, with a prevalence of 75% or higher in highly myopic eyes. In old age, highly myopic individuals have a high risk of eventually developing MMD with marked vision impairment.”

References:
  1. Bikbov MM, Gilmanshin TR, Kazakbaeva GM, Panda-Jonas S, Jonas JB. Prevalence of myopic maculopathy among the very old: The Ural Very Old Study. Invest Ophthalmol Vis Sci. 2024;65:29. doi: https://doi.org/10.1167/iovs.65.3.29
  2. Morgan IG, Ohno-Matsui K, Saw SM. Myopia. Lancet. 2012;379:1739–1748.
  3. Ohno-Matsui K, Kawasaki R, Jonas JB, et al. International classification and grading system for myopic maculopathy. Am J Ophthalmol. 2015;159:877–883.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.